Template:Travelers Diarrhea Antibiotics: Difference between revisions

No edit summary
No edit summary
Line 1: Line 1:
*[[Ciprofloxacin]] 750mg PO once daily x 1-3 days<ref>Hoge CW. et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis. 1998;26:341–5</ref>
*[[Ciprofloxacin]] 750mg PO once daily x 1-3 days<ref>Hoge CW. et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis. 1998;26:341–5</ref>
**First choice for use except in South and Southeast Asia
**First choice for use except in South and Southeast Asia<ref>Steffen R, et al. Traveler’s Diarrhea: A Clinical Review. JAMA. 2015;313(1):71-80. doi:10.1001/jama.2014.17006</ref>
*[[Azithromycin]] 500mg PO q24h x 3 days OR 1000mg PO x 1<ref>Sanders JW. et al. An observational clinic-based study of diarrheal illness in deployed United States military personnel in Thailand: presentation and outcome of Campylobacter infection. Am J Trop Med Hyg. 2002;67:533–8</ref>
*[[Azithromycin]] 500mg PO q24h x 3 days OR 1000mg PO x 1<ref>Sanders JW. et al. An observational clinic-based study of diarrheal illness in deployed United States military personnel in Thailand: presentation and outcome of Campylobacter infection. Am J Trop Med Hyg. 2002;67:533–8</ref>
**Nausea is a frequent adverse event
**Nausea is a frequent adverse event<ref>Steffen R, et al. Traveler’s Diarrhea: A Clinical Review. JAMA. 2015;313(1):71-80. doi:10.1001/jama.2014.17006</ref>
**First choice for use in South and Southeast Asia
**First choice for use in South and Southeast Asia<ref>Steffen R, et al. Traveler’s Diarrhea: A Clinical Review. JAMA. 2015;313(1):71-80. doi:10.1001/jama.2014.17006</ref>
*[[Rifaximin]] 200mg PO TID x 3 days<ref>DuPont HL. et al. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001;33:1807–15</ref>
*[[Rifaximin]] 200mg PO TID x 3 days<ref>DuPont HL. et al. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001;33:1807–15</ref>
**Ineffective against mucosally invasive pathogens ([[Shigella]], [[Salmonella]], [[Campylobacter]])
**Ineffective against mucosally invasive pathogens ([[Shigella]], [[Salmonella]], [[Campylobacter]])
**Considered very safe as it is not absorbed
**Considered very safe as it is not absorbed

Revision as of 23:36, 6 January 2015

  • Ciprofloxacin 750mg PO once daily x 1-3 days[1]
    • First choice for use except in South and Southeast Asia[2]
  • Azithromycin 500mg PO q24h x 3 days OR 1000mg PO x 1[3]
    • Nausea is a frequent adverse event[4]
    • First choice for use in South and Southeast Asia[5]
  • Rifaximin 200mg PO TID x 3 days[6]
  1. ↑ Hoge CW. et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis. 1998;26:341–5
  2. ↑ Steffen R, et al. Traveler’s Diarrhea: A Clinical Review. JAMA. 2015;313(1):71-80. doi:10.1001/jama.2014.17006
  3. ↑ Sanders JW. et al. An observational clinic-based study of diarrheal illness in deployed United States military personnel in Thailand: presentation and outcome of Campylobacter infection. Am J Trop Med Hyg. 2002;67:533–8
  4. ↑ Steffen R, et al. Traveler’s Diarrhea: A Clinical Review. JAMA. 2015;313(1):71-80. doi:10.1001/jama.2014.17006
  5. ↑ Steffen R, et al. Traveler’s Diarrhea: A Clinical Review. JAMA. 2015;313(1):71-80. doi:10.1001/jama.2014.17006
  6. ↑ DuPont HL. et al. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001;33:1807–15
Retrieved from "https://www.wikem.org/w/index.php?title=Template:Travelers_Diarrhea_Antibiotics&oldid=28465"